Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
Products for Apoptosis
- Caspase(99)
- 14.3.3 Proteins(1)
- Apoptosis Inducers(43)
- Bax(7)
- Bcl-2 Family(120)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(66)
- MDM2(12)
- p53(123)
- PC-PLC(4)
- PKD(7)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(145)
- Other Apoptosis(883)
- APC(6)
- PD-1/PD-L1 interaction(90)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(31)
- Cat.No. 产品名称 Information
-
GC19348
TAS-102
TAS-102
An orally bioavailable combination of a nucleoside analog and TPase inhibitor -
GC19346
Talampanel
(8R)-7-乙酰基-5-(4-氨基苯基)-8,9-二氢-8-甲基-7H-1,3-二氧杂环戊烯并[4,5-H][2,3]苯并二氮杂卓,GYKI-53773; LY-300164
An allosteric AMPA receptor antagonist -
GC19312
RO8994
An inhibitor of MDM2-p53 interaction
-
GC19306
RAD51 Inhibitor B02
B02
A RAD51 inhibitor -
GC19293
PFK-158
PFK-158 是一种有效的选择性 PFKFB3 抑制剂,通过减少癌细胞中葡萄糖的摄取、ATP 的产生、乳酸的释放以及诱导细胞凋亡和自噬,显示出广泛的抗肿瘤活性.PFK-158 在 EC 细胞中以剂量和时间依赖性方式抑制细胞活力。
-
GC19290
PF-3084014
PF-3084014; PF-03084014
An inhibitor of γ-secretase -
GC19268
NVP-HDM201
NVP-HDM201; HDM201
NVP-HDM201 (NVP-HDM201) 是一种有效的、口服生物利用度高且高度特异性的 p53-MDM2 相互作用抑制剂。 -
GC19263
NKP-1339
IT-139; KP-1339
A ruthenium complex with anticancer activity -
GC19257
MX69
An inhibitor of the MDM2 protein and XIAP RNA interaction
-
GC19254
ML385
ML385是一种特定的核因子红细胞2相关因子2(NRF2)抑制剂。
-
GC19248
Mivebresib
米维布塞; ABBV-075
A BRD2, BRD4, and BRDT inhibitor -
GC19225
PD-1-IN-1 (CA-170)
CA-170
PD-1-IN-1 (CA-170) 是一种具有口服活性的免疫检查点调节蛋白VISTA和PD-L1双重抑制剂。 -
GC19215
KRIBB11
An Hsf1 inhibitor
-
GC19200
INCB-057643
A BET family protein inhibitor
-
GC19199
Importazole
IPZ
A selective inhibitor of importin-β-mediated nuclear import -
GC19198
iCRT3
iCRT3 是 Wnt 和 β-连环蛋白反应性转录的抑制剂。
-
GC19197
IB-MECA
IB-MECA; CF-101
An adenosine A3 receptor agonist -
GC19195
Iberdomide
CC-220
A cereblon modulator -
GC19194
IACS-10759
5-(5-甲基-1-(3-(4-(甲基磺酰基)哌啶-1-基)苄基)-1H-1,2,4-三唑-3-基)-3-(4-(三氟甲氧基)苯基)-1,2,4-恶二唑,IACS-10759
IACS-10759 (IACS-010759) 是一种氧化磷酸化抑制剂,IACS-10759 是一种有效的氧化磷酸化复合物 I ( OXPHOS ) 抑制剂。 -
GC19185
GSK583
A selective inhibitor of RIP2 kinase
-
GC19182
GSK2982772
A RIPK1 inhibitor
-
GC19179
GSK2256098
A FAK inhibitor
-
GC19175
GSK-872
GSK-872 是一种 RIPK3 抑制剂。
-
GC19164
GGTI298 Trifluoroacetate
A geranylgeranyltransferase I inhibitor
-
GC19142
Erdafitinib
厄达替尼; JNJ-42756493
A pan-FGFR inhibitor -
GC19131
Tomivosertib
6'-[(6-氨基-4-嘧啶基)氨基]-8'-甲基螺[环己烷-1,3'(2'H)-咪唑并[1,5-A]吡啶]-1',5'-二酮,eFT508
A potent inhibitor of MNK1 and MNK2 -
GC19096
CDKI-73
LS-007
CDKI-73 (LS-007) 是一种具有口服活性且高效的 CDK9 抑制剂,对 CDK9、CDK1 和 CDK2 的 Ki 值分别为 4 nM、4 nM 和 3 nM。 -
GC19095
C-DIM12
4-Chlorophenyl-3,3'-diindolylmethane
An orally bioavailable activator of Nurr1 -
GC19088
CC122
Avadomide
A pleiotropic pathway modifier with anticancer activity -
GC19086
Calicheamicin
卡奇霉素; Calicheamicin γ1
加利车霉素是一种抗肿瘤抗生素,是一种导致双链 DNA 断裂的细胞毒剂。 -
GC19054
Azoramide
N-[2-[2-(4-氯苯基)-4-噻唑基]乙基]丁酰胺
An enhancer of ER protein-folding and chaperone activity -
GC19050
AZD5582
A Smac mimetic and IAP inhibitor
-
GC19046
AX-024 hydrochloride
An inhibitor of the CD3ε-Nck interaction
-
GC19041
ASK1-IN-1
ASK1-IN-1 是一种有效的、口服的、选择性的 ATP 竞争性凋亡信号调节激酶 1 (ASK1) 抑制剂,IC50 为 2.87 nM。
-
GC19037
ARS-853
An inhibitor of KRASG12C
-
GC18909
KRIBB3
An Hsp7 and inhibitor of microtubule polymerization
-
GC18852
S14161
8-乙氧基-2-(4-氟苯基)-3-硝基-2H-1-苯并吡喃
An inhibitor of cyclin D transactivation -
GC18847
RSM-932A
TCD-717
RSM-932A 是一种 ChoKα 抑制剂,对多种肿瘤来源的细胞系具有有效的体外抗增殖活性,对小鼠的人异种移植物具有体内抗肿瘤活性。
-
GC18832
Conglobatin
An Hsp90 inhibitor
-
GC18796
Herbicidin A
除莠菌素A
An adenine nucleoside antibiotic with herbicidal activity -
GC18787
(±)-Dunnione
2,3-二氢-2,3,3-三甲基萘并[1,2-B]呋喃-4,5-二酮
A naphthoquinone with diverse biological activities -
GC18769
MST-312
Telomerase Inhibitor IX
A telomerase inhibitor -
GC18751
Reticulol
网状菌醇
A cAMP phosphodiesterase and DNA topoisomerase I inhibitor -
GC18749
(+)-Rugulosin
细皱青霉素+FORM,(+)-Rugulosin
A mycotoxin -
GC18734
JS-K
A nitric oxide donor
-
GC18727
O-methyl Sterigmatocystin
O-甲基杂色曲霉素
An aflatoxin precursor -
GC18701
Hellebrin
蒜蘆黎素
An Na+/K+-ATPase inhibitor -
GC18677
YMU1
A thymidylate kinase inhibitor
-
GC18652
FQI 1
Factor Quinolinone Inhibitor 1
An inhibitor of Late SV40 Factor -
GC18641
Ferutinin
An ERα agonist